COMPLETE-2 Study: Revascularization for Heart Attack and Multivessel Disease

This study, called COMPLETE-2, is looking at the best way to treat people who have had a heart attack (acute myocardial infarction) and also have blockages in other heart arteries (multivessel disease). Researchers are comparing two approaches to clear these extra blockages: one guided by physiology (measuring blood flow) and another guided by angiography (X-ray imaging of blood vessels). The goal is to see if the physiology-guided approach is as good as or better than the angiography-guided approach in preventing future heart problems like another heart attack or death, and if it's safer. You might be able to join if you're 18 or older, have had a specific type of heart attack, and have other blockages that can be treated. The study plans to enroll 5100 participants, but its current status is unclear.

Study design
This is an interventional study comparing two treatment strategies. It is a randomized controlled trial, meaning participants will be assigned to one of the two treatment groups by chance. The study plans to enroll 5100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 2 years after the study begins to track their health outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05701358

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

Recruiting
NAAges 18+InterventionalTreatment
Population Health Research Institute
~5,100 participants
Updated 2025-06-19 on ClinicalTrials.gov
What's tested:Physiology-guided NCL PCIAngiography-guided NCL PCI

At a glance

Recruiting sites
113 of 113 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy: Time to first occurrence of the composite of CV death, new MI, or IDR
Measured over at study completion, a minimum of 2 years
+1 more outcome measured
Acute Myocardial Infarction
Coronary Artery Disease
113 sites across 32 states
Canada23
United Kingdom19
Germany7
Spain7
Sweden7
Italy6
New York4
Denmark3
  • Shamir Mehta, MD · PRINCIPAL_INVESTIGATOR · Population Health Research Institute

Opens a ready-to-send draft in your own email app — review before sending.

  • Efficacy: Time to first occurrence of the composite of CV death, new MI, or IDRat study completion, a minimum of 2 years
  • Safety: Time to first occurrence of the composite of clinically significant bleeding, stroke, stent thrombosis, or contrast-associated acute kidney injury.at study completion, a minimum of 2 years